Evaluation of EVT401, a P2X7 Receptor Antagonist, in Healthy Chinese Participants: a first-in-human, double-blind, randomized, placebo-controlled, dose-escalation trial.
PURPOSE As a critical hub between extracellular danger signals and intracellular inflammation, the P2X7 receptor centrally drives synovitis and joint destruction in rheumatoid arthritis, making it an attractive therapeutic target. This study reported the first-in-human data for EVT401, an orally administered P2X7 recep...